Drugs / SHR-3836
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07490613 | Jun 2026 → Apr 2028 expected | plasma cell myeloma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-3836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07490613 ↗ |